Bai SN, Wu Q, Song LY. Primary ovarian cancer combined with primary fallopian tube cancer: A case report. World J Clin Cases 2024; 12(17): 3188-3193 [PMID: 38898863 DOI: 10.12998/wjcc.v12.i17.3188]
Corresponding Author of This Article
Su-Ning Bai, MA, Attending Doctor, Department of Gynecology, Hebei General Hospital, 348 Heping West Road, Xinhua District, Shijiazhuang 050000, Hebei Province, China. 158494897@qq.com
Research Domain of This Article
Obstetrics & Gynecology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jun 16, 2024; 12(17): 3188-3193 Published online Jun 16, 2024. doi: 10.12998/wjcc.v12.i17.3188
Primary ovarian cancer combined with primary fallopian tube cancer: A case report
Su-Ning Bai, Qi Wu, Li-Yun Song
Su-Ning Bai, Qi Wu, Li-Yun Song, Department of Gynecology, Hebei General Hospital, Shijiazhuang 050000, Hebei Province, China
Author contributions: Bai SN and Song LY wrote original draft and analyzed the data; Bai SN contributed resources and software; Bai SN and Wu Q completed investigation and final writing, review and editing; and all authors have read and approve the final manuscript.
Informed consent statement: This report was prepared with the written consent of the patient.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Su-Ning Bai, MA, Attending Doctor, Department of Gynecology, Hebei General Hospital, 348 Heping West Road, Xinhua District, Shijiazhuang 050000, Hebei Province, China. 158494897@qq.com
Received: February 2, 2024 Revised: April 9, 2024 Accepted: May 6, 2024 Published online: June 16, 2024 Processing time: 123 Days and 2.4 Hours
Abstract
BACKGROUND
Low grade serous carcinoma of the ovary (LGSOC) is a rare type of epithelial ovarian cancer with a low incidence rate. The origin of ovarian cancer has always been a hot topic in gynecological oncology research, and some scholars believe that the origin of ovarian malignant tumors is the fallopian tubes. Primary fallopian tube cancer is the lowest incidence of malignant tumors in the female reproductive system. There are only a few reports in the literature, but the mortality rate is very high. But in clinical practice, fallopian tube cancer is very common, but in most cases, it is classified as ovarian cancer.
CASE SUMMARY
We report a 54 years old postmenopausal woman who was hospitalized with a lower abdominal mass and underwent surgical treatment. The final pathological confirmation was low-grade serous carcinoma of the right ovary and low-grade serous carcinoma of the left fallopian tube. No special treatment was performed after the surgery, and the patient was instructed to undergo regular follow-up without any signs of disease progression.
CONCLUSION
The prognosis of LGSOC is relatively good, over 80% of patients still experience disease recurrence.
Core Tip: Although the prognosis of low grade serous carcinoma of the ovary (LGSOC) is relatively good, over 80% of patients still experience disease recurrence. In most cases, these patients are relatively young and have the potential to receive active treatment and achieve a longer survival period. The treatment methods for LGSOC recurrence include re-tumor reduction surgery, chemotherapy, targeted therapy, hormone therapy and clinical trials. Currently, a large amount of research focuses on gene testing and targeted therapy. I hope that the progress of genome research and targeted therapy can change the therapeutic prospects of LGSOC and bring better therapeutic effects to patients with this disease.
